These dual mechanistic pathways highlight the critical role of ACTN1 in modulating the cellular response to cisplatin in HNSCC, substantiating its promise as a compelling target for therapeutic intervention. The gene discussed is ACTN1; the disease is head and neck squamous cell carcinoma.